NCT02095184 2026-04-15
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
Phase NA Terminated
Clinical Trials
32 trialsNCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT04113863 2025-12-18
ATRA
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01897441 2024-12-24
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT04714619 2023-12-19
CAILA
MedSIR
Phase 2 Terminated
NCT02585388 2023-09-06
CHEOPS
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT00543127 2023-03-10
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
Spanish Breast Cancer Research Group
Phase 3 Terminated
NCT03874325 2022-05-31
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02000596 2022-05-27
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
University of Maryland, Baltimore
Phase 2 Terminated
NCT01234532 2022-05-03
0927GCC
University of Maryland, Baltimore
Phase 2 Terminated
NCT02269670 2022-04-05
Phase II Study of Everolimus Beyond Progression
Emory University
Phase 2 Terminated
NCT03220178 2022-01-06
PRECYCLE
Palleos Healthcare GmbH
Phase 4 Terminated
NCT02730091 2021-02-01
VICTORIANE
Centre Hospitalier Universitaire de Besancon
Phase 3 Terminated
NCT02137837 2021-01-28
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
SWOG Cancer Research Network
Phase 3 Terminated
NCT02476955 2020-09-30
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT01394211 2018-07-26
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
University of Arizona
Phase 2 Terminated
NCT01776008 2018-05-08
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01484041 2018-02-09
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Georgetown University
Phase 1/2 Terminated
NCT00932152 2017-10-19
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00684216 2017-09-14
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT00661531 2017-04-12
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
Georgetown University
Phase 2 Terminated
NCT00481845 2017-02-07
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
Stanford University
Phase 2 Terminated
NCT00573755 2016-02-05
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT01262274 2015-05-21
Neo-ACET BC
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Terminated
NCT01368263 2015-04-03
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT00053911 2014-12-16
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
UNICANCER
Phase 3 Terminated
NCT01151215 2014-07-25
MINT
AstraZeneca
Phase 2 Terminated
NCT00555477 2014-06-19
Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00206414 2013-02-05
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
Baylor Breast Care Center
Phase 2 Terminated
NCT00437359 2012-03-30
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
Japan Breast Cancer Research Network
Phase 2 Terminated
NCT00303615 2008-10-20
Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer
Legacy Health System
Phase 2 Terminated